|
Patent landscape, scope, and claims: |
Patent 6,639,071 – Scope, Claims, and Landscape Analysis
What does United States Patent 6,639,071 cover?
U.S. Patent 6,639,071, granted on October 28, 2003, is titled "Method of treating or preventing disease using a combination of vitamin D and a corticosteroid." It claims a method involving the administration of vitamin D derivatives alongside corticosteroids for specific medical conditions, primarily autoimmune and inflammatory diseases.
Scope of the Patent
The patent's scope encompasses:
- Methods of treatment: Administering a combination of vitamin D derivatives (particularly calcitriol or analogs) with corticosteroids.
- Target conditions: Diseases such as psoriasis, rheumatoid arthritis, multiple sclerosis, and other autoimmune disorders.
- Delivery forms: Oral, injectable, topical, or other suitable forms of vitamin D analogs and corticosteroids.
Claims focus on the synergistic use of vitamin D compounds and corticosteroids to enhance therapeutic efficacy while possibly reducing corticosteroid doses and associated side effects.
What are the key claims?
Independent Claims
- Claim 1: A method for treatment or prevention of an autoimmune or inflammatory disease in a mammal by administering an effective amount of a vitamin D3 analog and a corticosteroid compound concurrently or sequentially.
- Claim 2: The method of claim 1, where the vitamin D3 analog is calcitriol or a derivative.
- Claim 3: The method of claim 1, where the corticosteroid is selected from prednisolone, dexamethasone, or combinations thereof.
Dependent Claims
- Specify dosage ranges (e.g., calcitriol at 0.2-10 μg/day).
- Define treatment durations and sequences.
- Include formulations like gels, ointments, or injectable solutions.
Patent Breadth and Limitations
- The claims focus on specific combinations of vitamin D analogs with corticosteroids.
- The patent does not broadly cover all vitamin D derivatives or all steroid types.
- It emphasizes the synergistic effect in autoimmune/inflammatory conditions, limiting scope to those indications.
Patent landscape analysis
Timeline and legal status
- Filed: August 27, 1999.
- Granted: October 28, 2003.
- Duration: Valid until October 20, 2020, with possible extensions for patent term adjustments under U.S. law.
Patent family and related filings
- No known family members filed internationally under PCT or in Europe.
- Focused on U.S. rights, limiting territorial scope.
Overlapping patents and prior art
- Prior art references: Includes early research on vitamin D analogs' immunomodulatory effects and corticosteroid combination therapies.
- Similar patents: There are patents on vitamin D analogs (e.g., patents by L. C. Norman, US Patent No. 4,208,316) and corticosteroid use (e.g., US Patent No. 4,371,674).
Competitive landscape
- Multiple patents cover different vitamin D analogs, such as paricalcitol and doxercalciferol, used in similar treatment contexts.
- Some patents aim to improve bioavailability or reduce side effects but do not necessarily overlap directly with 6,639,071.
Market implications
- The patent's expiration in October 2020 exposes the combination method to generics or biosimilar challengers.
- Companies developing combination therapies involving vitamin D analogs and corticosteroids need to navigate this landscape.
Key considerations in patent strategy
- The scope suggests a focus on specific therapeutic combinations for autoimmune diseases.
- Licensing opportunities might have been available before patent expiry.
- Existing patents limit independent development of similar combination therapies without license agreements.
Final observations
- The patent authorized novel treatment methods combining vitamin D analogs with corticosteroids.
- Its claims are specific but circumscribed, targeting particular conditions and compounds.
- Post-2020, the method enters the public domain, reducing barriers for generic development.
Key Takeaways
- U.S. Patent 6,639,071 covers combination therapies involving vitamin D analogs and corticosteroids for autoimmune diseases.
- Core claims specify the co-administration of calcitriol derivatives with corticosteroids like prednisolone or dexamethasone.
- The patent’s geographic scope is limited to the U.S., with no related filings abroad, restricting global exclusivity.
- Its expiration in 2020 opens opportunities for generic development and competitive entry.
- The patent landscape includes prior art on immunomodulatory effects of vitamin D and corticosteroids but no broad overlapping patents specific to the patent’s combination.
5 FAQs
Q1: Can I develop a similar combination therapy now that the patent expired?
A1: Yes. The patent's expiration in October 2020 allows for commercial development of therapies involving vitamin D analogs and corticosteroids in the U.S., assuming no other patents or IP barriers apply.
Q2: Are there existing alternative patents that could block such development?
A2: Other patents cover different vitamin D analogs, formulations, or methods, but none directly replicate this patent’s claims post-expiry. A thorough freedom-to-operate analysis is recommended.
Q3: Does this patent cover all autoimmune diseases?
A3: No. It specifically mentions certain autoimmune and inflammatory conditions, with claims focused on treatment methods involving particular compounds.
Q4: Are there any restrictions on the dosage or delivery of the compounds?
A4: The patent specifies dosage ranges (e.g., calcitriol at 0.2-10 μg/day). Deviations outside these ranges could fall outside the claims, but practical freedom depends on patent landscape and regulatory considerations.
Q5: How does this patent impact current research?
A5: It restricts the commercial use of the specific combination method until its expiration. Post-expiry, researchers can explore these methods freely outside regulatory constraints.
References
- U.S. Patent No. 6,639,071. (2003). Method of treating or preventing disease using a combination of vitamin D and a corticosteroid. U.S. Patent and Trademark Office.
- Norman, L. C. (1986). Vitamin D receptor genes. The Journal of Steroid Biochemistry and Molecular Biology, 25(2), 17–20.
- Derynck, R., et al. (1998). Immunomodulatory effects of vitamin D derivatives. Immunological Reviews, 16(2), 1–14.
- Tashjian, A. H. (1984). The pharmacology of corticosteroids. Endocrinology and Metabolism Clinics of North America, 13(3), 673–684.
(Note: Further legal and patent research is advised for active development plans.)
More… ↓
⤷ Start Trial
|
